|
1
|
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis.
|
Am J Physiol Gastrointest Liver Physiol
|
2005
|
4.28
|
|
2
|
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.
|
Gastroenterology
|
2007
|
3.99
|
|
3
|
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids.
|
J Exp Med
|
2014
|
2.98
|
|
4
|
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut.
|
J Immunol
|
2003
|
2.96
|
|
5
|
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine.
|
Gastroenterology
|
2006
|
2.78
|
|
6
|
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
|
Gastroenterology
|
2002
|
2.35
|
|
7
|
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
|
Am J Gastroenterol
|
2003
|
2.20
|
|
8
|
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.
|
Am J Gastroenterol
|
2008
|
2.16
|
|
9
|
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells.
|
J Immunol
|
2004
|
2.05
|
|
10
|
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis.
|
Am J Gastroenterol
|
2011
|
2.04
|
|
11
|
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
|
Gastroenterology
|
2003
|
1.95
|
|
12
|
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab.
|
Am J Gastroenterol
|
2005
|
1.93
|
|
13
|
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria.
|
Gastroenterology
|
2008
|
1.89
|
|
14
|
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events.
|
Am J Gastroenterol
|
2011
|
1.88
|
|
15
|
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
|
Gut
|
2011
|
1.80
|
|
16
|
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
|
Gastroenterology
|
2006
|
1.78
|
|
17
|
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.
|
J Immunol
|
2008
|
1.75
|
|
18
|
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders.
|
Semin Immunol
|
2009
|
1.66
|
|
19
|
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation.
|
Trials
|
2007
|
1.62
|
|
20
|
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
|
Clin Gastroenterol Hepatol
|
2012
|
1.57
|
|
21
|
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors.
|
Inflamm Bowel Dis
|
2009
|
1.53
|
|
22
|
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci.
|
PLoS Genet
|
2012
|
1.52
|
|
23
|
Defects in mucosal immunity leading to Crohn's disease.
|
Immunol Rev
|
2005
|
1.48
|
|
24
|
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
|
Gastroenterology
|
2006
|
1.43
|
|
25
|
An evidence-based systematic review on medical therapies for inflammatory bowel disease.
|
Am J Gastroenterol
|
2011
|
1.42
|
|
26
|
The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease.
|
Dig Dis Sci
|
2013
|
1.40
|
|
27
|
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis.
|
Am J Physiol Gastrointest Liver Physiol
|
2009
|
1.39
|
|
28
|
Exercise attenuates PCB-induced changes in the mouse gut microbiome.
|
Environ Health Perspect
|
2013
|
1.33
|
|
29
|
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.
|
Inflamm Bowel Dis
|
2007
|
1.33
|
|
30
|
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis.
|
Inflamm Bowel Dis
|
2010
|
1.28
|
|
31
|
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury.
|
Lab Invest
|
2010
|
1.23
|
|
32
|
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.
|
Gastroenterology
|
2006
|
1.20
|
|
33
|
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
|
Clin Gastroenterol Hepatol
|
2010
|
1.19
|
|
34
|
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
|
Am J Gastroenterol
|
2011
|
1.14
|
|
35
|
Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection.
|
Dig Dis Sci
|
2009
|
1.14
|
|
36
|
Pathogen recognition receptors, cancer and inflammation in the gut.
|
Curr Opin Pharmacol
|
2009
|
1.14
|
|
37
|
Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
|
Gastroenterology
|
2013
|
1.14
|
|
38
|
Advances in the pathogenesis of inflammatory bowel disease.
|
Curr Gastroenterol Rep
|
2006
|
1.12
|
|
39
|
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study.
|
BMC Med Genet
|
2011
|
1.10
|
|
40
|
TLR4 activates the β-catenin pathway to cause intestinal neoplasia.
|
PLoS One
|
2013
|
1.10
|
|
41
|
A pilot study of adalimumab in infliximab-allergic patients.
|
Inflamm Bowel Dis
|
2004
|
1.07
|
|
42
|
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2004
|
1.05
|
|
43
|
Predictors of aggressive inflammatory bowel disease.
|
Gastroenterol Hepatol (N Y)
|
2011
|
1.02
|
|
44
|
Biomarkers in inflammatory bowel disease.
|
Curr Opin Gastroenterol
|
2004
|
1.01
|
|
45
|
Innate immunity in the small intestine.
|
Curr Opin Gastroenterol
|
2012
|
1.01
|
|
46
|
Innate immunity in the small intestine.
|
Curr Opin Gastroenterol
|
2011
|
1.01
|
|
47
|
Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study.
|
Am J Gastroenterol
|
2012
|
1.00
|
|
48
|
Ulcerative colitis therapy: importance of delivery mechanisms.
|
Rev Gastroenterol Disord
|
2005
|
0.98
|
|
49
|
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis.
|
Innate Immun
|
2009
|
0.97
|
|
50
|
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease.
|
Inflamm Bowel Dis
|
2006
|
0.94
|
|
51
|
Cancer in inflammatory bowel disease: lessons from animal models.
|
Curr Opin Gastroenterol
|
2012
|
0.93
|
|
52
|
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia.
|
BMC Gastroenterol
|
2010
|
0.93
|
|
53
|
Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
|
Am J Gastroenterol
|
2007
|
0.88
|
|
54
|
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
|
Am J Surg Pathol
|
2004
|
0.87
|
|
55
|
Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease.
|
Virchows Arch
|
2011
|
0.87
|
|
56
|
How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice.
|
Inflamm Bowel Dis
|
2008
|
0.86
|
|
57
|
Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients.
|
Inflamm Bowel Dis
|
2008
|
0.85
|
|
58
|
Increased toll-like receptor 4 in cerebral endothelial cells contributes to the astrocyte swelling and brain edema in acute hepatic encephalopathy.
|
J Neurochem
|
2013
|
0.85
|
|
59
|
Microflora in colorectal cancer: a friend to fear.
|
Nat Med
|
2010
|
0.84
|
|
60
|
The innate immune system and inflammatory bowel disease.
|
Scand J Gastroenterol
|
2015
|
0.82
|
|
61
|
Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.
|
Inflamm Bowel Dis
|
2010
|
0.82
|
|
62
|
Practical techniques for detection of Toll-like receptor-4 in the human intestine.
|
Methods Mol Biol
|
2009
|
0.82
|
|
63
|
In silico and Ex vivo approaches identify a role for toll-like receptor 4 in colorectal cancer.
|
J Exp Clin Cancer Res
|
2014
|
0.82
|
|
64
|
Lipopolysaccharide potentiates polychlorinated biphenyl-induced disruption of the blood-brain barrier via TLR4/IRF-3 signaling.
|
Toxicology
|
2012
|
0.81
|
|
65
|
Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.
|
Curr Opin Drug Discov Devel
|
2005
|
0.81
|
|
66
|
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
|
Inflamm Bowel Dis
|
2016
|
0.80
|
|
67
|
Design issues and outcomes in IBD clinical trials.
|
Inflamm Bowel Dis
|
2005
|
0.79
|
|
68
|
Host-microbe interactions in the small bowel.
|
Curr Opin Gastroenterol
|
2015
|
0.79
|
|
69
|
Re: underrepresentation of underrepresented minorities in academic medicine.
|
Gastroenterology
|
2010
|
0.79
|
|
70
|
What are toll-like receptors and what role may they have in IBD?
|
Inflamm Bowel Dis
|
2008
|
0.79
|
|
71
|
Use of capsule endoscopy for established Crohn's disease.
|
Gastrointest Endosc Clin N Am
|
2006
|
0.79
|
|
72
|
FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease.
|
Inflamm Bowel Dis
|
2009
|
0.78
|
|
73
|
What is the role and significance of serum and stool biomarkers in the diagnosis of IBD?
|
Inflamm Bowel Dis
|
2008
|
0.78
|
|
74
|
Update on idiopathic colitides.
|
Curr Opin Gastroenterol
|
2013
|
0.77
|
|
75
|
Genetics in diagnosing and managing inflammatory bowel disease.
|
Gastroenterol Clin North Am
|
2012
|
0.77
|
|
76
|
Harnessing the power of bacteria to protect the gut.
|
N Engl J Med
|
2008
|
0.77
|
|
77
|
New insights into the pathogenesis of inflammatory bowel disease.
|
Curr Gastroenterol Rep
|
2004
|
0.76
|
|
78
|
Gut microbes in Crohn's disease: getting to know you better?
|
Am J Gastroenterol
|
2008
|
0.76
|
|
79
|
Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study.
|
Gastroenterol Hepatol
|
2007
|
0.76
|
|
80
|
Use of Cancer Stem Cells to Investigate the Pathogenesis of Colitis-associated Cancer.
|
Inflamm Bowel Dis
|
2016
|
0.75
|
|
81
|
Combination therapy with infliximab and immunomodulators: is the glass half empty?
|
Gastroenterology
|
2008
|
0.75
|
|
82
|
Defining subtypes of Crohn's disease patients: the ground work for translational research in inflammatory bowel disease.
|
J Clin Gastroenterol
|
2003
|
0.75
|
|
83
|
Is genetic testing in IBD ready for prime time?
|
Am J Gastroenterol
|
2004
|
0.75
|
|
84
|
Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn's Disease.
|
Inflamm Bowel Dis
|
2016
|
0.75
|
|
85
|
Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis.
|
J Clin Gastroenterol
|
2011
|
0.75
|